Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > Japan suspends 1.6 million doses of Moderna shot after contamination reports
    Top Stories

    Japan suspends 1.6 million doses of Moderna shot after contamination reports

    Published by Wanda Rich

    Posted on August 26, 2021

    7 min read

    Last updated: January 21, 2026

    This image highlights Japan's suspension of 1.63 million doses of the Moderna COVID-19 vaccine due to reported contamination. The decision affects vaccination plans amid safety investigations.
    Japan suspends Moderna COVID-19 vaccine doses due to contamination concerns - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    By Rocky Swift

    TOKYO (Reuters) -Japan suspended the use of 1.63 million doses of Moderna Inc’s COVID-19 vaccine on Thursday, more than a week after the domestic distributor received reports of contaminants in some vials.

    Both Japan and Moderna said no safety or efficacy issues had been identified and the suspension was just a precaution. But the move prompted several Japanese companies to cancel worker vaccinations planned for Thursday.

    “Moderna confirms having been notified of cases of particulate matter being seen in drug product vials of its COVID-19 vaccine,” the U.S. vaccine maker said in a statement, adding it put the lot in question and two adjacent lots on hold.

    “The company is investigating the reports and remains committed to working expeditiously with its partner, Takeda, and regulators to address this,” it added, referring to Japan’s Takeda Pharmaceutical, which distributes the vaccine in the country.

    A Health Ministry official said Takeda first found out about the contaminated vials on Aug. 16 and reported the issue to the government on Wednesday. The delay was because Takeda needed time to gather information on which vials were affected and where they were in the country, the official said.

    Moderna said the contamination could be due to a manufacturing issue in one of the production lines at its contract manufacturing site in Spain.

    A spokesperson for the company added that the affected production batch, plus two more batches held back out of caution because they were processed before and after the affected batches, were meant for distribution only in Japan.

    Spanish pharma company Rovi, which bottles or “fills and finishes” Moderna vaccines for markets other than the United States, said it is investigating possible contamination of Moderna doses and the issue appeared to be limited to a few batches bound for Japan.

    Shares in Rovi dropped 4.6%.

    The suspension is a fresh setback for Moderna, whose partners had production delays last month that disrupted supplies to countries including South Korea.

    Japan’s defence ministry, which operates a mass vaccination site in Osaka, said shots from the lot in question, which contains 565,400 doses, had been used in the western prefecture between Aug. 6 and Aug. 20, but it did not say how many people were affected.

    Japanese carrier ANA said about 4,700 shots of the halted Moderna lot had been used and it would stop all vaccinations planned on Thursday.

    Its rival Japan Airlines also cancelled some COVID-19 vaccinations for its employees on Thursday after receiving Moderna vaccines with particulate matter.

    Despite several companies cancelling planned vaccinations, Prime Minister Yoshihide Suga said the country’s inoculation plan would be little affected by the issue.

    A day earlier, he said about 60% of the public would be fully vaccinated by the end of September and the country had enough vaccines to provide booster doses.

    The decision to suspend use of the Moderna shots comes at an awkward time for Suga, whose government was criticised over a slow rollout in the vaccine campaign earlier in the year. He faces challenges in a party leadership race and his approval ratings have sunk below 30%.

    Japan is battling its worst wave of infections, driven by the Delta variant, with new daily infections exceeding 25,000 this month for the first time. It has inoculated 54% of its population with at least one dose and fully vaccinated 43%, according to a Reuters vaccine tracker.

    (Reporting by Manojna Maddipatla and Nikhil Kurian Nainan in Bengaluru, Chang-Ran Kim and Rocky Swift in Tokyo and Ju-min Park, Nathan Allen and Sangmi Cha in Seoul, and Ludwig Burger in Frankfurt; Editing by Ana Nicolaci da Costa and David Holmes)

     

    By Rocky Swift

    TOKYO (Reuters) -Japan suspended the use of 1.63 million doses of Moderna Inc’s COVID-19 vaccine on Thursday, more than a week after the domestic distributor received reports of contaminants in some vials.

    Both Japan and Moderna said no safety or efficacy issues had been identified and the suspension was just a precaution. But the move prompted several Japanese companies to cancel worker vaccinations planned for Thursday.

    “Moderna confirms having been notified of cases of particulate matter being seen in drug product vials of its COVID-19 vaccine,” the U.S. vaccine maker said in a statement, adding it put the lot in question and two adjacent lots on hold.

    “The company is investigating the reports and remains committed to working expeditiously with its partner, Takeda, and regulators to address this,” it added, referring to Japan’s Takeda Pharmaceutical, which distributes the vaccine in the country.

    A Health Ministry official said Takeda first found out about the contaminated vials on Aug. 16 and reported the issue to the government on Wednesday. The delay was because Takeda needed time to gather information on which vials were affected and where they were in the country, the official said.

    Moderna said the contamination could be due to a manufacturing issue in one of the production lines at its contract manufacturing site in Spain.

    A spokesperson for the company added that the affected production batch, plus two more batches held back out of caution because they were processed before and after the affected batches, were meant for distribution only in Japan.

    Spanish pharma company Rovi, which bottles or “fills and finishes” Moderna vaccines for markets other than the United States, said it is investigating possible contamination of Moderna doses and the issue appeared to be limited to a few batches bound for Japan.

    Shares in Rovi dropped 4.6%.

    The suspension is a fresh setback for Moderna, whose partners had production delays last month that disrupted supplies to countries including South Korea.

    Japan’s defence ministry, which operates a mass vaccination site in Osaka, said shots from the lot in question, which contains 565,400 doses, had been used in the western prefecture between Aug. 6 and Aug. 20, but it did not say how many people were affected.

    Japanese carrier ANA said about 4,700 shots of the halted Moderna lot had been used and it would stop all vaccinations planned on Thursday.

    Its rival Japan Airlines also cancelled some COVID-19 vaccinations for its employees on Thursday after receiving Moderna vaccines with particulate matter.

    Despite several companies cancelling planned vaccinations, Prime Minister Yoshihide Suga said the country’s inoculation plan would be little affected by the issue.

    A day earlier, he said about 60% of the public would be fully vaccinated by the end of September and the country had enough vaccines to provide booster doses.

    The decision to suspend use of the Moderna shots comes at an awkward time for Suga, whose government was criticised over a slow rollout in the vaccine campaign earlier in the year. He faces challenges in a party leadership race and his approval ratings have sunk below 30%.

    Japan is battling its worst wave of infections, driven by the Delta variant, with new daily infections exceeding 25,000 this month for the first time. It has inoculated 54% of its population with at least one dose and fully vaccinated 43%, according to a Reuters vaccine tracker.

    (Reporting by Manojna Maddipatla and Nikhil Kurian Nainan in Bengaluru, Chang-Ran Kim and Rocky Swift in Tokyo and Ju-min Park, Nathan Allen and Sangmi Cha in Seoul, and Ludwig Burger in Frankfurt; Editing by Ana Nicolaci da Costa and David Holmes)

     

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostEU Commission warns negative changes to UK data rules may jeopardise data deal
    Next Top Stories PostJ&J says booster dose increased antibodies in early-stage studies